Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis.

hemophilia A hemophilia B postpartum hemorrhage pregnancy von Willebrand diseases

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 07 01 2024
revised: 13 06 2024
accepted: 02 07 2024
medline: 21 8 2024
pubmed: 21 8 2024
entrez: 21 8 2024
Statut: epublish

Résumé

Between 2002 and 2011, the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with von Willebrand disease (VWD) and hemophilia carriers (HCs) was 8% vs 4.5% in the general population. To determine the contemporary incidence of severe primary PPH in women with VWD and HCs. All women with VWD or HCs who delivered between 2012 and 2017 were selected from all 6 Dutch hemophilia treatment centers. Data on patient and disease characteristics, peripartum hematologic and obstetric management, and outcomes were retrospectively collected. Incidence of severe primary (≥1000 mL of blood loss ≤24 hours after childbirth) and primary (≥500 mL within ≤24 hours after childbirth) PPH was compared with the (1) previous cohort and (2) general Dutch population and between (3) women with VWD and HCs with third-trimester coagulation activity levels <50 international units (IU)/dL vs ≥50 IU/dL and (4) women treated with vs without peripartum hemostatic prophylaxis. Three-hundred forty-eight deliveries (151 VWD, 167 hemophilia A, and 30 hemophilia B carriers) were included. The severe primary PPH incidence was 10% (36/348) and remained stable over time, whereas this incidence has increased in the general population (to 8%), leading to a similar risk ( Severe primary PPH in women with VWD and HCs remained stable and is comparable with the increasing prevalence in the general population. More research is needed to find the optimal pregnancy management strategy for safe delivery in VWD and HC.

Sections du résumé

Background UNASSIGNED
Between 2002 and 2011, the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with von Willebrand disease (VWD) and hemophilia carriers (HCs) was 8% vs 4.5% in the general population.
Objectives UNASSIGNED
To determine the contemporary incidence of severe primary PPH in women with VWD and HCs.
Methods UNASSIGNED
All women with VWD or HCs who delivered between 2012 and 2017 were selected from all 6 Dutch hemophilia treatment centers. Data on patient and disease characteristics, peripartum hematologic and obstetric management, and outcomes were retrospectively collected. Incidence of severe primary (≥1000 mL of blood loss ≤24 hours after childbirth) and primary (≥500 mL within ≤24 hours after childbirth) PPH was compared with the (1) previous cohort and (2) general Dutch population and between (3) women with VWD and HCs with third-trimester coagulation activity levels <50 international units (IU)/dL vs ≥50 IU/dL and (4) women treated with vs without peripartum hemostatic prophylaxis.
Results UNASSIGNED
Three-hundred forty-eight deliveries (151 VWD, 167 hemophilia A, and 30 hemophilia B carriers) were included. The severe primary PPH incidence was 10% (36/348) and remained stable over time, whereas this incidence has increased in the general population (to 8%), leading to a similar risk (
Conclusion UNASSIGNED
Severe primary PPH in women with VWD and HCs remained stable and is comparable with the increasing prevalence in the general population. More research is needed to find the optimal pregnancy management strategy for safe delivery in VWD and HC.

Identifiants

pubmed: 39165610
doi: 10.1016/j.rpth.2024.102508
pii: S2475-0379(24)00203-6
pmc: PMC11334897
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102508

Informations de copyright

© 2024 The Author(s).

Auteurs

Marieke Punt (M)

University Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.

Fe van Leusden (F)

University Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.

Kitty Bloemenkamp (K)

Department of Gynecology and Obstetrics, Utrecht, the Netherlands.

Michiel Coppens (M)

Department of Vascular Medicine, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, the Netherlands.
Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands.

Mariette Driessens (M)

Netherlands Hemophilia Patient Society, Nijkerk, the Netherlands.

Floor Heubel-Moenen (F)

Department of Haematology-Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.
Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.

Titia Lely (T)

Department of Gynecology and Obstetrics, Utrecht, the Netherlands.

Anja Mäkelburg (A)

Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.

Laurens Nieuwenhuizen (L)

Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Department of Thrombosis and Hemostasis, Maxima Medical Center, Veldhoven, the Netherlands.

Saskia Haitjema (S)

University Medical Center Utrecht, University Utrecht, Laboratory of Clinical Chemistry and Hematology, Utrecht, the Netherlands.

Wouter van Solinge (W)

University Medical Center Utrecht, University Utrecht, Laboratory of Clinical Chemistry and Hematology, Utrecht, the Netherlands.

Joline Saes (J)

Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.

Saskia Schols (S)

Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, the Netherlands.
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.

Roger Schutgens (R)

University Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.

Jeroen Eikenboom (J)

Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.

Marieke Kruip (M)

Department of Hematology Erasmus MC, Erasmus University Medical Center, Rotterdam, the Netherlands.

Karin van Galen (K)

University Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, the Netherlands.

Classifications MeSH